p73 as a pharmaceutical target for cancer therapy.

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• The p53 tumor suppressor pathway is frequently disrupted in human cancers.
• The p53-family, including p73 and p63, plays a critical role in cell cycle control and apoptosis.
• p73 is crucial for chemotherapy response and can substitute for p53 in DNA damage-induced cell death.

Purpose of the Study:

• To provide an overview of p73 regulation mechanisms.
• To highlight the therapeutic potential of targeting the p73 pathway in cancer.
• To discuss pharmacological strategies for modulating p73 activity.

Main Methods:

• Review of existing literature on p73 biology and regulation.
• Analysis of signaling networks involving p53-family proteins.
• Discussion of pharmacological agents targeting p73 modulators or interactors.

Main Results:

• The p53-family pathway is a central network regulating cell fate.
• p73, despite its complex functions, is rarely mutated in tumors, making its pathway druggable.
• Pharmacological tools can be developed to increase p73 accumulation and function.

Conclusions:

• Targeting the p73 pathway represents a promising strategy for cancer drug development.
• Understanding p73 regulation is essential for improving cancer treatment outcomes.
• Drug repositioning and novel molecule development targeting p73 hold significant therapeutic potential.